So far, the ADC brentuximab vedotin—which targets CD30, an antigen expressed by embryonal carcinoma—has not exhibited clinically meaningful single-agent activity in patients with refractory GCTs in a phase II clinical trial [39,40]. Here, TNFRSF8 is linked to embryonal carcinoma.